Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data
Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, each of whom brings specialized expertise that aligns with Nexalin's Alzheimer's-focused initiatives. The restructured SAB will play a pivotal role in guiding the Company's scientific direction, clinical strategy, and biomarker-driven trial design for neurodegenerative and neuropsychiatric disorders.
'This enhanced advisory board reflects our sharpened focus on Alzheimer's disease, and the high-caliber expertise of Drs. Huang, Owens, and Scheer aligns with our expanding research agenda,' said Mark White, CEO of Nexalin Technology. 'Their combined contributions will be invaluable as we advance Nexalin's technology through clinical trials designed to address one of the greatest public health challenges of our time.'
Nexalin's Gen-2 SYNC and Gen-3 Halo™ headset delivers DIFS™, a proprietary waveform capable of penetrating deep brain structures implicated in cognitive decline and mental illness. Recent published articles and encouraging preclinical and early-stage human data suggest that DIFS™ may promote neuroplasticity and functional recovery in regions associated with memory and executive function. These findings have prompted the Company to intensify its focus on Alzheimer's disease, with the SAB's restructuring aimed at providing the scientific and clinical oversight required for this complex area of medicine.
Scientific Advisory Board Members
Dr. Mingxiong Huang is a globally recognized expert in magnetoencephalography (MEG) and neuroimaging, with over 25 years of experience developing and applying advanced imaging techniques to neurological and psychiatric disorders. He is Professor of Radiology at the University of California, San Diego (UCSD), Adjunct Professor in the Department of Electrical and Computer Engineering, Co-Director of the UCSD MEG Center, and a career research health scientist at the VA San Diego Healthcare System.
Dr. Huang earned his Ph.D. in biomedical physics from Northeastern University and completed postdoctoral training in MEG at Los Alamos National Laboratory. He previously held faculty positions at the University of New Mexico before joining UCSD. His work has been instrumental in advancing MEG source imaging, integrating MEG with structural and functional modalities such as diffusion tensor imaging, and applying these methods to conditions including TBI, PTSD, stroke, epilepsy, and schizophrenia. He has authored over 90 peer-reviewed publications and received the Distinguished Investigator Award from the Academy of Radiology Research. Dr. Huang's deep expertise in brain imaging biomarkers directly supports Nexalin's mission to develop data-driven, non-invasive therapies for Alzheimer's and other neurodegenerative disorders.
Dr. Abe Scheer served on the Company's prior SAB and brings more than four decades of experience in adult and pediatric neurology, psychiatry, brain injury medicine, and electrophysiology. Board certified by the American Board of Psychiatry and Neurology in both adult and pediatric neurology, as well as in brain injury medicine, Dr. Scheer has trained and held faculty positions at premier institutions including Columbia University, Cornell Medical College, Georgetown University, and the University of Pittsburgh. Dr. Scheer held the position of Director of Neurology and Stroke Services at Beebe Healthcare in Delaware for over 10 years. He is currently a neurohospitalist and neurointensivist at Bay Health in Delaware and maintains an attending role at MeadowWood Hospital in Delaware.
Dr. Scheer has lectured extensively across the U.S. on neuromodulation therapies and was instrumental in launching the first vagal nerve stimulation and baclofen pump clinics in Lincoln, Nebraska. He has served in advisory capacities for leading device developers including Medtronic, Cyberonics, and Milestone Scientific. A passionate educator, he continues to teach medical students and residents while contributing to clinical advancements in both neurology and psychiatry. His expertise will play a critical role in supporting Nexalin's efforts to deliver innovative, non-pharmacological solutions for Alzheimer's and related disorders.
Dr. David Owens serves as the Company's Chief Medical Officer and is a board-certified neuroradiologist and interventional neuroimaging specialist with more than 25 years of experience in brain and spine imaging. A graduate of Furman University and the Medical University of South Carolina, Dr. Owens completed residency and fellowship training at Emory University Hospital, where he specialized in interventional therapies for brain disorders before entering private practice. His expertise includes traumatic brain injury, neurocognitive disorders, and sports-related brain trauma.
Dr. Owens is a nationally recognized leader in advanced imaging techniques such as diffusion tensor imaging (DTI) and functional MRI. Over the past decade, he has also conducted and contributed to clinical research on transcranial stimulation therapies for conditions including anxiety, insomnia, clinical depression, and chronic pain—particularly in the context of reducing opioid dependency. Today, he operates a national teleradiology consultation practice focused on outpatient neuroimaging and continues to serve as a strategic clinical advisor in emerging neuromodulation technologies.
'This is a critical moment for innovation in Alzheimer's treatment,' said Dr. Scheer. 'Nexalin's technology represents a novel approach to brain modulation that could complement or even exceed the efficacy of traditional pharmacological therapies, particularly in the early stages of disease.'
The Company plans to initiate new Alzheimer's-focused clinical studies in the third quarter of 2025, incorporating cognitive testing, imaging biomarkers, and MEG-guided metrics to assess treatment efficacy and neural activation. The SAB will be instrumental in optimizing trial designs and ensuring adherence to regulatory standards and scientific rigor.
'I am excited to work alongside Nexalin's leadership and fellow SAB members to help guide the next generation of non-invasive neuromodulation therapies,' added Dr. Huang. 'The intersection of neuroimaging, brain stimulation, and clinical science holds enormous potential for treating neurodegenerative disease.'
This SAB reconstitution underscores Nexalin's continued evolution as a science-driven company committed to transforming mental health and neurodegenerative disease care through advanced bioelectronic medicine.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15-milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Forward-looking statements
This press release contains statements that constitute 'forward-looking statements,' These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management 'believes', 'expects', 'anticipates', 'plans', 'intends' and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
12 minutes ago
- National Post
The Cannabist Company Announces Closing on Sale of Affiliate; Repositioning to a Wholesale Strategy in Pennsylvania
Article content NEW YORK — The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) ('The Cannabist Company' or the 'Company'), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today the successful closing of the sale of its Pennsylvania affiliate that owns 3 medical dispensaries ('Pennsylvania Transaction') to VP Investment Holdings, LLC ('VP Holdings'). VP Holdings is comprised of principals from a leading privately-held dispensary operator in Pennsylvania, Restore Integrative Wellness Center, LLC. The sale will include a concurrent supply agreement with VP Holdings for products produced by Cannabist's grow/processing affiliate, Green Leaf Medicals, LLC ('gLeaf'). This strategic Pennsylvania Transaction accelerates The Cannabist Company's wholesale cultivation presence by enhancing the commercialization of its state-of-the-art grow-processor facility located in Saxton, Pennsylvania, while continuing to serve the broader medical market through high-quality medical marijuana. Article content Pennsylvania Transaction Highlights Article content VP Holdings acquired Columbia Care Pennsylvania LLC, from Columbia Care LLC via Equity Purchase Agreement for approximately $10 million in cash paid at closing. Columbia Care Pennsylvania's 3 operational medical dispensaries are located in Scranton, Allentown and Wilkes-Barre, Pennsylvania. VP Holdings expects to rebrand all 3 locations to the Restore brand immediately. As additional consideration, VP Holdings and Restore have entered into a supply agreement with The Cannabist Company (through gLeaf), thereby expanding The Cannabist Company's wholesale distribution footprint in Pennsylvania. The Cannabist Company will continue to enhance and expand its wholesale presence in-state by driving the performance of its Saxton grow-processor facility. Article content The Cannabist Company Management Commentary Article content 'This Pennsylvania Transaction is a clear example of executing on our strategic plan to simplify our business and optimize existing assets, while delivering immediate financial benefits,' stated David Hart, CEO of The Cannabist Company. 'We've taken a proactive and thoughtful step that strengthens our balance sheet, bolsters liquidity, and enhances our operational focus. By divesting our retail footprint in Pennsylvania for all cash and entering into a meaningful wholesale agreement, we are now better positioned to optimize our best-in-class Saxton cultivation facility and expand distribution of our high-quality products to patients across the state. This transaction positions us to better capitalize on the current medical landscape and future opportunities in a potential adult-use market.' Article content CLD Advisory served as exclusive financial advisor and Foley Hoag LLP served as legal advisor, while Cannabis Law Solutions served as Pennsylvania regulatory counsel to The Cannabist Company. Ballard Spahr LLP acted as legal advisor to Restore. Article content The Cannabist Company, formerly known as Columbia Care, is one of the most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 12 U.S. jurisdictions. The Company operates 77 facilities including 61 dispensaries and 16 cultivation and manufacturing facilities, including those under development. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information, please visit Article content Caution Concerning Forward-Looking Statements Article content This press release contains certain statements that constitute 'forward-looking information' or 'forward-looking statements' within the meaning of applicable securities laws and reflect the Company's current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the Company's ability to execute on the Pennsylvania Transaction and on its repositioning to a wholesale strategy in Pennsylvania. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. In addition, security holders should review the risk factors discussed under 'Risk Factors' in Columbia Care's Form 10-K for the year ended December 31, 2024, as filed with Canadian and U.S. securities regulatory authorities and described from time to time in subsequent documents filed with applicable securities regulatory authorities. Article content Article content Article content Article content Article content Contacts Article content Investor Contact Article content Article content Lee Ann Evans Article content Article content Article content Article content
National Post
12 minutes ago
- National Post
TEN (Transportation Equipment Network) Appoints Nathan Smith as Interim Chief Executive Officer
Article content DUBLIN, Ohio — TEN (Transportation Equipment Network), a leading trailer leasing company owned by I Squared Capital, a leading global infrastructure investor, today announced that Nathan Smith, TEN's Chief Operating Officer, has been appointed interim Chief Executive Officer, effective immediately. Article content Nathan Smith joined TEN in December 2024, bringing decades of leadership experience in the transportation and logistics industry. Prior to TEN, he spent much of his career at JB Hunt, where he held senior leadership roles including Senior Vice President of Equipment and Properties and Senior Vice President of Intermodal Operations. Article content In recent months, TEN has continued to strengthen its market leadership with the launch of TEN Ready, a disaster recovery initiative designed to deliver trailers in times of crisis; the upcoming introduction of an industry leading, patent pending customer solution at TEN Cool, and its geographic expansion into the Houston and Pacific Northwest markets through collaboration programs with industry recognized 'agent' partners. These strategic initiatives underscore TEN's commitment to innovation, customer service, and long-term growth. Article content Tom Donohue, Chairman, TEN, said: 'Nathan is a highly respected leader with a deep understanding of our business and industry. His operational expertise and steady leadership make him the right person to guide TEN through this transition and ensure we continue on our growth trajectory. The Board would like to thank Scott Nelson for his service and leadership, and we are grateful for his cooperation during this transition.' Article content Nathan Smith, Interim CEO, TEN, said: 'Our top priority is serving our customers with the reliability and excellence they expect from TEN. I am deeply committed to ensuring that our customers and our people remain well-supported as we continue to strengthen operations and empower our teams. It is an honor to step into the role of interim CEO at such an important time for TEN, and I look forward to building on the company's strong foundation and position as an industry leader.' Article content About TEN (Transportation Equipment Network) Article content Headquartered in Dublin, OH, TEN (Transportation Equipment Network) is the largest full-service trailer lessor in North America. With approximately 86,000 trailers, 1,000 employees, 249 service shop bays, 130 mobile service trucks, 300 mechanics, 100 road technicians, and nearly 50 locations across the United States and Canada, TEN is equipped to seamlessly serve customers across North America. TEN provides full-service leasing as well as maintenance, advanced technological solutions, consultation services, and other innovative offerings across numerous industry verticals. To learn more, visit Article content I Squared Capital is a leading global infrastructure investor managing $45 billion in assets. We build and scale essential infrastructure businesses that deliver critical services to millions of people worldwide. Our portfolio includes over 90 companies operating in more than 70 countries and spanning sectors such as energy, utilities, digital infrastructure, transport, environmental and social infrastructure. Headquartered in Miami, our team of over 300 professionals is based across offices in Abu Dhabi, London, Munich, New Delhi, São Paulo, Singapore, Sydney and Taipei. Learn more at Article content Article content Article content Article content Contacts Article content Media Contacts: Article content TEN Article content Article content Melanie March Article content
Globe and Mail
32 minutes ago
- Globe and Mail
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
Key Points AbbVie has performed better than the market over the past decade. The company has lost a major product, but its lineup and pipeline remain strong. AbbVie still has a solid business and boasts a strong dividend program. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate greater shareholder value by focusing on its main area of expertise, which, for AbbVie, is the development and marketing of pharmaceutical products. Did the move produce the desired effect? One way to determine whether it has is to check AbbVie's performance over the past decade against that of the broader market. Let's look into that, and also try to determine if AbbVie is a worthwhile investment. It's been a terrific investment Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's significantly better than the performance of the S&P 500. If you had invested $1,000 in AbbVie 10 years ago, you'd have $4,530.75, compared to just $3,690.99 for the S&P 500. ^SPX data by YCharts. How did AbbVie manage to pull that off? The most important asset the company had through this period was its immunology drug Humira. In the U.S. alone, it has been approved for 12 indications, including Crohn's disease, psoriatic arthritis, and plaque psoriasis. The medicine's sales consistently grew at a good clip, helping AbbVie generate stable financial results. The drugmaker hit a speed bump in 2018, when Humira's patent expired in Europe and the company faced biosimilar competition there. Revenue from the blockbuster medicine dropped slightly, but due to continued momentum in the U.S., its sales began moving in the right direction again. Humira went on to become the best-selling medicine in the history of the industry, hitting a peak of $22.1 billion before losing patent protection in the U.S. in 2023. The future is still bright What's next for AbbVie, now that it's effectively lost the most important asset that allowed it to perform so well after splitting from Abbott? The company is moving on thanks to two other immunology products, Skyrizi and Rinvoq. Both were first approved in the U.S. in 2019 and have since won various label expansions. Together, Skyrizi and Rinvoq significantly overlap with Humira's indications; in some cases, they're more effective than their predecessor. For instance, one study found that Skyrizi was more effective than Humira in plaque psoriasis. Between them, Skyrizi and Rinvoq should more than fill Humira's shoes. Management predicts that the two will combine for $31 billion in sales by 2027, significantly surpassing the $22.1 billion Humira achieved at its peak. And AbbVie's next-generation immunology superstars should continue growing their sales for a long time after that -- they haven't even been on the market for a decade yet. That all paints a bright picture for the company's future, especially when considering the rest of its business. AbbVie closed its acquisition of Allergan for $63 billion in 2020, gaining access to key products, including its Botox franchise and schizophrenia treatment Vraylar. AbbVie's lineup features a range of other medicines that are helping drive top-line growth, such as Qulipta for migraine, and cancer drug Venclexta. The company also has a deep pipeline and routinely expands it thanks to acquisitions or licensing deals. In March, it announced an agreement with Denmark-based Gubra A/S for the development of GUB014295, for weight management, an area of the pharmaceutical industry that's catching fire. This move may or may not pan out, but AbbVie's extensive pipeline should allow it to replenish its lineup before it has to deal with patent cliffs for Skyrizi and Rinvoq. Lastly, AbbVie is an excellent dividend payer. The company has increased its payouts by 221.6% over the past decade and stands as one of the Dividend Kings, with 53 consecutive years of payout increases, including the time it spent under the wing of its former parent company. AbbVie also offers a juicy forward yield of 3.2%, much higher than the S&P 500's average of 1.3%. AbbVie isn't done beating the market: The stock could still deliver over the next decade, especially for those who opt to reinvest the dividend. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
